Efforts to characterize HIV-1 polymorphism and anti-HIV immune response are being made in areas where anti-HIV/AIDS vaccines are to be employed. Anti-HIV-1 humoral immune response is being studied in infected individuals resident in Rio de Janeiro, in distinct cohorts involving recent seroconvertors, pregnant women or intravenous drug users (IDU). Comparative analyses of specificity of antibody response towards epitopes important for anti-HIV-1 immune response indicate quantitative differences between cohorts, with an exceptionally strong response in IDUs and weakest response in pregnant women. However, a comparative analysis between pregnant women cohorts from Rio de Janeiro and Rio Grande do Sul indicated an even lower response (with exception of the anti-V3-C clade peptide recognition) for the southern cohort. Studies analysing the immune function of the humoral response indicate a quite elevated occurrence of antibodies capable of neutralizing heterologous primary HIV-
Attempts to develop anti-HIV/AIDS vaccines have been checked by the great genetic variability of HIV-1 (Bloom 1996) . Genotyping studies have subdivided HIV-1 into several subtypes, while serotyping analyses have not lead to a definition of distinct HIV-1 serotypes (Moore & Trkola 1997) . A clustering of "serospecificities" based on binding of antibodies to synthetic peptides corresponding to genotypic subtypes indicate a partial correspondence between genotype and serotype , Simon et al. 1996 . However, analyses of the functional HIV neutralizing humoral response has not indicated a correlation with HIV-1 genotypes (Weber et al. 1996) but a "grouping" of sera with similar neutralization potency and cross-clade activity (Trkola et al. 1995 , Kostrikis et al. 1996 , Nyambi et al. 1996 . The need for an anti-AIDS vaccine concomitant to HIV-1 variability motivates studies of viral polymorphism in the different geographic regions with high prevalence of HIV infection, in parallel to studies on specific human immune response to the various clades in the different areas. Identification of specific immune reactivities (Fenyö et al. 1996) and analyses of its potential protectivity against development of immune deficiency in HIV infection is needed for development and evaluation of effective vaccine candidates.
This report presents results of several studies of humoral immune response against HIV-1 in Rio de Janeiro, Brazil, in different patient cohorts to allow comparative evaluations.
MATERIALS AND METHODS
Patients -Data is presented from different patient groups: (a) Vertical HIV transmission group (TV-RJ), accompanied at the Hospital Evandro Chagas, Instituto Oswaldo Cruz, RJ; the Hospital Geral de Nova Iguaçu, RJ and the Hospital dos Servidores do Estado, RJ, comprised of 125 HIV-1 infected pregnant women and women that had given birth recently; (b) 30 individuals from an injecting drug user (IDU) cross-sectional study, comprised of a mostly male group (97%), of the "Projeto Brasil", Centro de Informações em Ciência e Tecnologia, Fiocruz, RJ, and NEPAD, Universidade Estadual do Rio de Janeiro; (c) 85 asymptomatic HIV-1 infected individuals resident in Rio de Janeiro (RN-RJ), Hospital Evandro Chagas; (d) a cohort of 51 pregnant asymptomatic HIV-1 infected women resident in Rio Grande do Sul (TV-RS), accompanied by the Secretaria da Saúde e Meio Ambiente, Porto Alegre, RS.
Seroreactivity -Duplicates of sequentially diluted heat inactivated plasma were incubated with different biotinylated synthetic peptides bound to multiwell plates precoated with streptavidin. Specific reactivity was assessed (including 8M urea washes) by peroxidase-conjugated anti-human-IgG binding and H 2 O 2 /TMB revelation (Bastos et al. 1997) . Reactivity was assessed as dilution titer reaching at least twice the mean binding of the two control plasma included in each assay plate. The variation of total numbers of plasma analyzed derives from exclusion of data from doubtful analyses.
Neutralization assay -Supernatants from primary co-cultures collected between the 7th and 21st day of co-culture were used as viral stocks. The standard assay employing pre-incubation of viral dilutions with heat inactivated plasma followed by addition of phytohemagglutinin-activated normal human PBMC (Albert et al. 1990 . Changes of at least 90% of the medium after 24 and 48 hr were carried out in order to eliminate eventually present anti-p24 antibodies in the plasma used ). Evaluation of neutralization was carried out by measurement of the HIV-1 p24 antigen (DuPont HIV-1 antigen assay) in the culture supernatants on day 7. Neutralization was considered positive when a reduction of at least 75% of viral input was detected as measured by p24 concentration .
Heteroduplex mobility assay (HMA) -The test was carried out according to Delwart et al. (1993) using the reagents indicated. Differentiation between B subtype and the B" variant of subtype B was carried out using analysis of Fok 1 restriction enzyme fragments by agarose gel electrophoresis .
Statistical analyses -Fisher's exact test was used for statistical evaluation (significance defined as p<0.05).
RESULTS

SEROREACTIVITY
Seroreactivity of plasma from the IDU cohortAnalyses of basic social-demographic and clinical data showed that the three groups here assessed: IDUs, homo and bisexual males (sexual transmission -males, RN cohort), and females infected through sexual intercourse (sexual transmissionfemales, TV-RJ cohort) have comparable distribution along age ranges and clinical staging, although the TV cohort included 46% of pregnant women at plasma collection.
Higher reactivity against all peptides tested was observed for the IDU vis-à-vis sexually infected plasma, both considering whole groups (Table I) and matching by clinical stages, with differences in peptide recognition more expressive in more advanced clinical stages (data not shown). Reactivity with epitopes important for HIV-1 neutralization outside of the V3-loop (V2, gp41 735-752) was especially high in IDU plasma (Table II) .
Seroreactivity of vertical transmission cohorts -In consideration to the size of Brazil (8.511.965 km 2 ) and regional HIV-1 polymorphism described earlier , a comparative analysis between vertical HIV-1 transmission cohorts from Rio de Janeiro (RJ, southeast region) and Rio Grande do Sul (RS, south region) was carried out. Unfortunately, little clinical data from the TV-RS cohort was available, but all women were pregnant, with HIV-1 positive sorological diagnosis with no clinical indication of infection (asymptomatic). The TV-RJ cohort included 43% of symptomatic women. Comparing reactivities of plasma from Rio Grande do Sul with plasma from different cohorts from Rio de Janeiro, lower reactivity was generally observed for TV-RS. Comparing reactivities with a vertical transmission cohort from Rio de Janeiro, reactivity towards V3-B was still significantly lower for the southern plasma, as was also detected after correction regarding clinical staging. Interestingly, reactivity with the V3-C peptide was similar for plasma from individuals resident in either region, irrespective of corrections according to clinical data (Table III) . Seroreactivity versus genotype -Attempts to correlate seroreactivity and genotype were undertaken to evaluate the utility of serotyping Brazilian HIV-1. As the HIV-1 subtypes circulating in Brazil up to now (July 1997) have been identified as clades B (including variant B"), F and C, seroreactivity against "consensus" peptides of these clades/variants was assayed.
The results indicate that 73% of the sera from individuals infected with the B" variant of the B subtype could be identified by serological reactivity (plasma with either exclusive or stronger reactivity against the homologous genotype peptide), while 5.4% of the sera would be wrongly typed (exclusive or stronger reactivity with heterologous genotype peptides) based on peptide recognition data ( Fig. 1) . However, sera from individuals infected with the classical B subtype or the F subtype showed no specific recognition of the corresponding V3 peptides, and percentages of plasma with a higher reactivity against a peptide representative of another clade/variant ("wrongly typed") was very high (57% of sera from individuals infected with the classical B clade HIV-1). The percentage of plasma with no possibility of serotyping (no reactivity or with similar reactivity with the peptides) was highest for plasma from individuals infected with clade F HIV-1 (Table IV) .
NEUTRALIZATION
Heterologous neutralization -Susceptibility assays were carried out with 18 primary HIV-1 isolates derived from patients of the TV-RJ cohort, indicating a higher susceptibility to neutralizing antibodies of the Brazilian primary isolates than described in the literature (Montefiori et al. 1991 , Arendrup et al. 1993 , Bjoerling et al. 1993 , Pilgrim et al. 1997 ; when plasma diluted to 1:10 were employed, 169 of 223 tests (76%) resulted in a neutralization greater than 75%; using 1:50 diluted plasma, 73 of 88 combinations showed neutralization efficacy greater than 75%. Only 2 of the 18 isolates tested showed very low susceptibility to heterologous neutralization . A representative chequer-board neutralization assay comparing susceptibilities of two primary HIV-1 isolates and the reference HIV-1 MN strain is shown in Table V . Neutralization versus genotype -Crossed neutralization was assayed for 42 clade B HIV-1 isolates, 20 B" variants of B clade HIV-1 and 2 F clade isolates, against plasma from individiduals infected with clade B (n=42), variant B" (n=24) or clade F (n=9). Fig. 2 presents an overview of the results obtained.
DISCUSSION
Reactivity of plasma from HIV-1 infected individuals with synthetic peptides corresponding to classical B subtype HIV-1 isolates referred to in vaccine candidate development has indicated a higher reactivity in North America/Europe in comparison to other geographic areas (Carrow et al. 1991 , Pau et al. 1994 ). More recent data show that, although the B subtype of HIV-1 is predominant in Brazil (Potts et al. 1993) , as described for North America and Europe, the typical GPGR amino acid sequence at the top of the gp120 envelope V3 loop is substituted by GWGR in a significant number of Brazilian HIV-1 subtype B isolates ), now being designated B" variant of the classical B genotype. Other HIV-1 clades and recombinations of clades have been detected in Brazil by different research groups (as reviewed in . Regional predominance of HIV-1 subtypes has been indicated and more recently confirmed by Hendry et al. (1996) and several studies presented at the 2nd Brazilian Symposium on Basic Research in HIV/AIDS in 1997.
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Only one study comparing plasma from different regions of Brazil was carried out, including corrections for clinical data of the different cohorts. It has been known that reactivity with the consensus V3-B peptide is lower in Brazil than described for North America or Europe (Carrow et al. 1991 , Cheingsong-Popov et al. 1992 . Recognition of V3-B peptides (including V3-B") was even lower in the southern than in the southeastern region, while recognition of the V3-C consensus peptide was at similar levels, confirming indications of a higher prevalence of C subtype HIV-1 in the south of Brazil. Recognition of the V3-FBR peptide, although lower for southern plasma, was not significantly lower observed with Rio de Janeiro plasma, when correction for clinical data was included. The lower reactivity observed in the TV cohort reflects the lower overall immune response normally observed in pregnant women (Mikyas et al. 1997 ), but appears to be a characteristic of the southern region, as it was evident even in comparison with a clinically matched cohort from Rio de Janeiro, indicating that there is a shift in HIV-1 subtype distribution in Brazil. Such a shift could be significant for vaccine trials: if the data presented here is confirmed for other HIV-1 infected groups with different exposure risks, considerations valid for African vaccine trials (where the C subtype is the most prevalent, according to UNAIDS, Geneva, Switzerland) will have to be applied, at least for the south of Brazil.
Correlation between genotype and serotype in HIV-1 infection has not been established as yet. While serotyping of Thailandese sera of individuals infected with genotypes B or E is possible (Wasi et al. 1995) with some exceptions (Louisirirotchanakul et al. 1997) , no such correlation between genotype and serotype could be established between infections with other HIV-1 clades (Moore & Trkola 1997) . In the present study, analysis of serotype and genotype indicates that no important differences between clade B and F peptides could be observed testing plasma from clade B or clade F infected individuals. Cross-reactivity was also high in respect to the C peptide. However, an identification of the variant B" HIV-1 infection may be possible: only 2 of 37 plasma showed preferential recognition of non B" peptides.
As no valid correlation between seroreactivity and HIV-1 neutralization has been established (Nyambi et al. 1997) , in vitro assays are needed to identify effective antibody activity. Neutralization susceptibility of primary HIV-1 isolates has been described as being quite low (Lathey et al. 1997) . In the present study extensive cross-neutralization has been shown to exist between HIV-1 isolates from HIV-1 infected women and heterologous plasma from the same cohort. A chequer-board neutralization comparing two primary HIV-1 isolates with similar tissue culture infectivity and the reference HIV-1 isolate MN (similar infectious doses used) indicates extensive cross-neutralization: of 42 plasma tested, 31 were able to neutralize all 3 isolates (and 7/17 tested using both 1:10 and 1:50 diluted plasma). The cross-neutralization effect could not be correlated to the HIV-1 genotype, and could be shown to be more extensive than the cross-recognition of clade specific V3-loop peptides. This extensive cross-neutralization observed between HIV-1 subtypes prevalent in Rio de Janeiro, including the B" variant of clade B, indicates the importance of epitopes outside of the V3-loop for the induction of neutralizing antibodies. Although two other epitopes known to be important for the induction of neutralizing antibodies (V2-loop peptides and the gp41 735-752 peptide, Cheingsong-Popov et al. 1992 ) have been employed in the seroreactivity assays, no important recognition of these epitopes could be observed in plasma with high neutralization potency.
The data shown indicate that the heterogeneity of HIV-1 infection is very high in Brazil, as described elsewhere: not only differences between cohorts defined by distinct exposure categories but also between individuals from distinct geographical regions. However, although more studies have to be carried out before final conclusions can be drawn, these differences in seroreactivity and genotype may not be of significant biological relevance, as indicated by the neutralization susceptibility/ potency studies which do not distinguish HIV-1 subtypes/variants circulating in Rio de Janeiro, Brazil.
